Catalent (NYSE:CTLT) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Catalent (NYSE:CTLT) issued its earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18), Briefing.com reports. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period last year, the business earned ($0.10) EPS. The company’s revenue for the quarter was up 4.2% on a year-over-year basis.

Catalent Stock Down 0.1 %

Shares of Catalent stock traded down $0.06 during trading hours on Thursday, hitting $59.89. The company had a trading volume of 2,188,452 shares, compared to its average volume of 2,049,834. The company’s 50-day moving average is $60.01 and its two-hundred day moving average is $58.05. Catalent has a twelve month low of $32.38 and a twelve month high of $61.20. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. The company has a market cap of $10.87 billion, a P/E ratio of -10.91, a price-to-earnings-growth ratio of 2.06 and a beta of 1.16.

Insider Activity

In related news, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Robert W. Baird restated a “neutral” rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. Finally, StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $59.83.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.